Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Crosses Above Fifty Day Moving Average – Should You Sell?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s share price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $34.08 and traded as high as $37.11. Collegium Pharmaceutical shares last traded at $36.59, with a volume of 1,618,493 shares changing hands.

Analysts Set New Price Targets

Several equities research analysts have issued reports on COLL shares. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Weiss Ratings cut Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. Needham & Company LLC restated a “buy” rating and issued a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, March 20th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Stock Up 5.0%

The firm has a market cap of $1.19 billion, a price-to-earnings ratio of 17.94 and a beta of 0.74. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. The stock has a 50-day moving average of $34.08 and a 200-day moving average of $39.67.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.24. The firm had revenue of $193.52 million during the quarter, compared to analysts’ expectations of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.49 EPS. Sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the business. Vident Advisory LLC lifted its position in shares of Collegium Pharmaceutical by 1.9% during the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock worth $541,000 after buying an additional 281 shares during the last quarter. Quadrant Capital Group LLC grew its position in Collegium Pharmaceutical by 4.2% in the fourth quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock valued at $324,000 after acquiring an additional 282 shares during the last quarter. GAMMA Investing LLC raised its stake in Collegium Pharmaceutical by 9.6% during the fourth quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock worth $151,000 after acquiring an additional 285 shares in the last quarter. Atom Investors LP raised its stake in Collegium Pharmaceutical by 5.0% during the fourth quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock worth $284,000 after acquiring an additional 294 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Collegium Pharmaceutical by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 318 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.